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Abstract
Single neuron firing rate was recorded from dorsal raphe nucleus of anesthetized rats. The firing rate of raphe neurons varied from 4 to 8
discharge per second before drug administration and this neuronal activity was decreased by L-701,324 (2 mg/kg i.v. injection), a competitive
antagonist of glycineB binding site of N-methyl-D-aspartate (NMDA) receptors. The glycine transporter type-1 (GlyT1) antagonists Org-24461
(10 mg/kg i.v.) and NFPS (3 mg/kg i.v.) reversed the inhibitory effect of L-701,324 on single neuron activity recorded from dorsal raphe nucleus of
the rat. Org-24461 and NFPS both tended to increase the raphe neuronal firing rate also when given alone but their effect was not significant. This
finding serves further evidence that glutamate released from axon terminals of the cortico-striatal projection neurons stimulates serotonergic
neurons in the raphe nuclei and this effect is mediated at least in part by postsynaptic NMDA receptors. Thus, GlyT1 inhibitors are able to reverse
the hypofunctional state of NMDA receptors, suggesting that these drugs may have beneficial therapeutic effects in neurological and psychiatric
disorders characterized with impaired NMDA receptor-mediated transmission.
# 2007 Elsevier Ltd. All rights reserved.
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1. Introduction
The dorsal raphe nucleus (DRN) in the brainstem contains at
least 50% of all serotonergic neurons of the central nervous
system (Wiklund and Bjorklund, 1980). These neurons are
medium sized cells with spiny dendritic arborization, which
establish local neuronal network with their dendrodendritic
connections and recurrent axon collaterals. Beside serotonergic
projection neurons, DRN also contains GABAergic interneurons
as well as numerous noradrenergic and glutamatergic axon
terminals.Morphological and functional observations confirmed
the existence of a glutamatergic pathway arising from themedian
prefrontal cortex (Behzadi et al., 1990; Hajos et al., 1998)
whereas serotonergic neurons of DRN form extended projection
to the cerebral cortex (Kidd et al., 1991; Sesack et al., 1989).
Thus, the raphe-cortical serotonergic and the cortico-raphe
glutamatergic projections establish a long-axon neuronal loop
between these two brain structures. Interaction between
glutamatergic axon terminals and serotonergic neurons forms
an excitatory-inhibitory connection by which incoming excita-
tory signals are converted into inhibitory output projecting back
to cerebral cortex where stimulation was generated from.
The primary target of the cortical glutamatergic neurons
within the raphe nuclei is the serotonergic projection neurons
www.elsevier.com/locate/neuint
Neurochemistry International 52 (2008) 130–134
* Corresponding author. Tel.: +36 1 401 4221; fax: +36 1 407 4888.
E-mail address: harsing.laszlo@egis.hu (L.G. Harsing Jr.).
0197-0186/$ – see front matter # 2007 Elsevier Ltd. All rights reserved.
doi:10.1016/j.neuint.2007.06.030
Author's personal copy
(Tao et al., 1996; Harsing et al., 2004). The excitatory
glutamatergic influence in DRNmay be mediated by ionotropic
glutamate receptors expressed in postsynaptic membrane of
serotonergic neurons. In isolated raphe nuclei slices, activation
of N-methyl-D-aspartate (NMDA) receptors evokes serotonin
release (Harsing et al., 2004). The NMDA receptor requires
glycine as cotransmitter for its activation (Johnson and Ascher,
1987). At synaptic level, glutamate is released from glutama-
tergic axon terminals and glycine is released from astroglial
cells. Being released into the synaptic cleft, they diffuse to the
vicinity of postsynaptic NMDA receptors (Zafra et al., 1997).
Operation of glycine transporter type-1 (GlyT1) expressed in
astocytes assures to set glycine concentrations at NMDA
receptor below saturating levels (Bergeron et al., 1998).
Inhibition of GlyT1 enforces NMDA receptor-mediated
functions, particularly in conditions when glycineB binding
site at NR1 subunit is blocked by selective inhibitors (Danysz
and Parson, 1998). The aim of the present study was to
investigate whether the GlyT1 inhibitors Org-24461 and NFPS
(Fig. 1) are able to facilitate glutamate-mediated excitation of
serotonergic projection neurons in rat DRN.
2. Experimental procedure
2.1. Animals and drugs
Male Wistar rats weighing 250–300 g were obtained from Charles River
Hungary. The animals were housed up to five to a cage in a temperature- and
humidity-controlled animal facility on a 12-h light:12-h dark cycle (6.00 a.m.
on; 6.00 p.m. off) with food and water available ad libitum. The animals were
allowed at least 1 week of habituation to their housing prior to experimentation.
NFPS, N[3-(40-fluorophenyl)-3-(40phenylphenoxy)-propyl]sarcosine
(Herdon et al., 2001) and Org-24461, R,S-()N-methyl-N-[(4-trifluoro-
methyl)phenoxy]-3-phenyl-propylglycine (Brown et al., 2001) were synthe-
sized by Dr. Peter Matyus, Department of Organic Chemistry, Semmelweis
University, Budapest, Hungary. Org-24461 (50 mg/ml) and NFPS (10 mg/
ml) were dissolved in dimethyl sulfoxide (DMSO), briefly sonicated and
kept in a water bath at 37 8C for ca. 10 min. Immediately before admin-
istration; they were diluted in a double volume of saline. L-701,324 was
purchased from Tocris Bioscience (Bristol, UK) and dissolved in 25%
polyethylene glycol (PEG)-300 and 75% saline. Intravenous administration
of drug vehicle alone showed no change in single-unit activity. Urethane was
purchased from Reanal (Budapest, Hungary). All other chemicals were of
analytical grade.
2.2. Recording single neuron activity from rat DRN
Rats were anesthetized with urethane (1 g/kg i.p.). A polyethylene cannula
was inserted into the left femoral vein. Then the head of the animals was fixed,
the skull was opened on a 6 mm  6 mm square around the lambda point using
a dental drill and the dura was cut. The opening was sealed with bone wax, and
the animal was put aside for at least 30 min. For recording, the rat was mounted
in a stereotaxic frame (Narishige SR-6N) and a wolfram microelectrode (World
Precision Instruments, WPI TM33B20) was advanced into the area of DRN
(AP: 8; L: 0; and V: 5.8–6.5 mm, Paxinos and Watson, 1998) by a single axis
micromanipulator (Narishige SM15). Extracellular single-unit activity was
recorded and amplified, amplified gain: 1000; low-pass filter at 0.1 kHz,
high-pass filter 5 kHz. The amplified biological signals were registered in a
Tektronix oscilloscope and sampled by a PC-based computer using Neurosys
1.1.0.357 software (Experimetria, Hungary). As soon as the firing in DRN
reached a stabile rate, control activity was recorded for 10 min. Then, with
uninterrupted recording, L-701,324 was injected i.v. in a dose of 2 mg/kg and
activity was recorded for another 10-min period. GlyT1 inhibitors were added
i.v. (Org-24461 10 mg/kg, NFPS 3 mg/kg) and neuronal single-unit activity was
further recorded for a 10-min period.
To verify the position of the microelectrode, dc current (1 mA for 15 s) was
delivered through the recording electrode when all recording was completed.
The animals received then an overdose of urethane and were perfused transcar-
dially with saline followed by buffered formalin. Brain sections (70 mm)
containing the raphe nuclei were cut using a freezing microtome and the
sections were washed, dehydrated with alcohol and Nissl staining was used for
evaluation. A further proof that activity of neurons from a correct location was
recorded was provided by changes in neuronal activity after L-701,324 admin-
istration (see below).
2.3. Evaluation of the records and statistical analysis
For evaluation, the records were played back and a threshold level was set so
that all extracellular spikes, but no noise, crossed it. Crossings were counted as
events, from which neuronal firing rate was calculated by the software. For data
analysis, firing rates were collected for 250 s before injection of L-701,324
(control period) and for 250 and 500 s periods before and after the administration
of the GlyT1 inhibitors. All group data were presented as mean S.D. and one-
way analysis of variance (ANOVA) followed by the least significant difference
(LSD) tests were used to compare differences between group mean data with
control group mean. Differences between control and experimental responses
with P < 0.05 were considered significant, n indicate the number of experiments.
3. Results
Our preliminary experiments indicated that single neuron
firing registered from rat DRN was due to activation of
Fig. 1. The chemical structures of the glycine transporter type-1 inhibitors Org-24461 and NFPS.
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serotonergic neurons. This was evidenced by firing rate
characteristics (Blier et al., 1992) and by the fact that i.v.
administration of 8-OH-DPAT, and 5-HT1A receptor agonist,
markedly reduced neuronal firing rate in DRN of the rat.
During the control period the rate of neuronal single-unit
firing, recorded from DRN of anesthetized rats varied between
3 and 8 Hz with no excessive variations in time (Fig. 2A). Then,
in the first series of experiments, L-701,324 was injected i.v. in
a dose of 2 mg/kg, which reduced firing rate significantly by
approximately 50% (Table 1). This effect increased the
detection sensitivity of the putative effect of the agent tested,
indicated that the recorded activity was of DRN neurons having
glutamate receptors. Org-24461, injected in a dose of 10 mg/kg
i.v. 3–5 min after L-701,324 administration, raised the firing
rate of DRN approximately to the control level (Fig. 2A and
Table 1). The increase started within 1 min after injection,
peaked at 4–5 min and then ceased gradually.
In the second series of experiments, 2 mg/kg L-701,324 was
injected as before and it decreased neuronal firing rate in DRN
by ca. 70% (Table 1). On i.p. administration of 3 mg/kg NFPS,
this decrease was reversed (Fig. 2B and Table 1), so that the
firing rate was higher than that in the control. The time course of
the rate change was similar to that seen after Org-24461.
4. Discussion
It has been suggested that hypofunction of NMDA receptors
may be involved in the etiology of schizophrenia (Coyle et al.,
2003). The glutamatergic theory of schizophrenia is based upon
the cognitive and behavioral effects of the NMDA receptor
antagonist phencyclidine (PCP) and ketamine in animals and
human. In fact, subanesthetic doses of dissociative anaesthetics
exacerbate psychotic symptoms, reverse remission in schizo-
phrenic patients and evoke psychotic state in normal subjects
(Millan, 2002). The similarities of PCP-precipitated behavior
with appearance of symptoms of schizophrenia have prompted
the use of PCP and ketamine in pharmacological models of
schizophrenia in both preclinical and clinical studies (Mathe´,
1998).
A reduced NMDA receptor function has been established in
our study by using L-701,324, an antagonist on glycineB binding
site of NMDA receptor that readily crosses the blood–brain
barrier.We found that blockade of glycineB binding sites inDRN
reduces single neuron firing rate and this inhibition can be
suspended by subsequent administration of GlyT1 inhibitors.
Similarly to our finding, it has been shown that GlyT1 inhibition
potentiates NMDA-mediated neuronal cell firing responses in rat
prefrontal cortical neurons (Chen et al., 2003). We have shown
previously that stimulation of NMDA receptors leads to increase
of serotonin release from rat raphe nuclei slices (Harsing et al.,
2004). The present experiments, showing enhanced neuronal
firing rate after indirect activation of NMDA receptors by GlyT1
inhibitors, are in accordance. Thus, both in vitro and in vivo
experiments served direct evidence for the existence of a
glutamatergic–serotonergic interaction in the raphe nuclei.
The prefrontal cortex receives serotonergic innervation from
DRN (Hajos et al., 1998). The raphe-cortical projection exerts
stimulation of GABA interneurons through 5-HT2A receptors
and inhibition of glutamatergic pyramidal cells via 5-HT1A
receptors in the prefrontal cortex (Carlsson et al., 1997;
Aghajanian and Marek, 2000). This dual action of serotonin
results in an increased GABAergic inhibition and a reduced
glutamatergic stimulation in cortical neuronal circuitry. The
GABA/glutamate balance in the prefrontal cortex may be
particularly important in schizophrenia when the impaired
thalamic filter leads to increased transmission of sensory
information from the periphery to the cerebral cortex
(Aghajanian and Marek, 2000). The extreme levels of sensory
inputs disrupt integrative cortical functions, which mirrors in
Fig. 2. The effects of the GlyT1 inhibitor Org-24461 (A) and NFPS (B) on
single neuron firing rate in DRN of anesthetized rats. Org-24461 and NFPS
were injected i.v. in doses of 10 and 3 mg/kg, respectively, after inhibition of
neuronal firing by the glycineB binding site antagonist L-701,324. L-701,324
was administered to rats in an i.v. dose of 2 mg/kg. ANOVA followed by the
least significant difference test (LSD), mean  S.D., n = 6 in Org-24461-treated
group and n = 11 in NFPS-treated group.
Table 1
Effect of Org-24461 and NFPS on single neuron firing rate recorded from dorsal
raphe nucleus of anesthetized rats
Control L-701,324
(2 mg/kg)
Org-24461
(10 mg/kg)
Frequency (Hz) 7.92  8.97 3.64  6.55*** 7.64  11.35###
Control L-701,324
(2 mg/kg)
NFPS
(3 mg/kg)
Frequency (Hz) 3.69  0.42 1.05  0.27*** 4.95  1.96###
Single-unit activity was recorded from DRN of anesthetized rats. L-701,324, a
glycineB binding site competitive antagonist, and Org-24461 and NFPS,
inhibitors of GlyT1, were administered i.v. in doses indicated. Mean  S.D.,
n = 6 in Org-24461-treated group and n = 11 in NFPS-treated group. ANOVA
followed by the least significant difference (LSD) test.
*** P < 0.001 vs. control.
### P < 0.001 vs. L-701,324.
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desynchronized EEG activity and hallucinations (Sebban et al.,
2002).
In schizophrenia, NMDA receptors in the central nervous
system may be impaired (Tamminga, 1998) and those expressed
in the cellmembrane of raphe serotonergic neuronsmight also be
altered. Decreased activity of glutamate carboxy peptidase and
variants in the gene for neuroregulin I have been implicated to
explain NMDA receptor hypofunction in subjects with schizo-
phrenia (Lewis and Gonzalez-Burgos, 2006). Since cortical
glutamatergic input activates raphe serotonergic neurons via
NMDA receptors (Harsing et al., 2006), their hypofunctional
state will lead to reduced serotonergic transmission in their axon
terminal fields, including the prefrontal cortex.
Direct agonists of glycineB binding site may restore NMDA
receptor hypofunctionality characteristics for psychotic state
(Millan, 2002) and GlyT1 inhibitors may act accordingly
(Mork et al., 2005). GlyT1 inhibitors will increase availability
of synaptic glycine at NMDA receptors and restoration of
glutamatergic influence on raphe serotonergic neurons may
normalize GABA/glutamate balance in the cerebral cortex
leading to an overall inhibition in prefrontal neuronal circuitry.
Thus, effects of GlyT1 inhibitors on raphe nuclei NMDA
receptors may be part of their antipsychotic action reported
earlier (Javitt, 2002; Harsing et al., 2003, 2005; Thomsen,
2006). The potential site of action of GlyT1 inhibitors in the
neuronal circuitry of DRN is shown in Fig. 3.
There have been a number of publications indicating the
disruption of raphe neurochemical transmission in schizophrenia
or animal models of psychosis (Akhondzadeh, 2001; Craven
et al., 2005).Thus, raphe serotonergic pathways have been shown
to participate in psychotomimetic drug-induced locomotion and
prepulse inhibition in rats (Kusljic and van den Buuse, 2004).
Furthermore, it has been shown that destruction of raphe
serotonergic neuronsby theneurotoxin 5,7-dihydroxytryptamine
enhances the psychomimetic effects of phencyclidine (Kusljic
et al., 2005). The present findings serve additional information to
the potential role of midbrain raphe nuclei in the pathology of
psychosis and may provide further evidence for the potential
antipsychotic role of drugs inhibiting GlyT1.
GlyT1, which may be involved in mediation of schizo-
phrenia, has been detected in different locations in the CNS
(Fig. 3). The primarily action of synaptic GlyT1 is regulation of
glycine concentrations in glutamatergic synapses (Aragon and
Lopez-Corcuera, 2005) whereas those located nonsynaptically
establish glycine concentration gradient between the extra-
synaptic solution and within the synapse (Vandenberg and
Aubrey, 2001). Thus, GlyT1 inhibitors may alter not only
glycine concentrations within the synaptic cleft (Javitt, 2007)
but also in other brain compartments, such as the extracellular
space as revealed by microdialysis studies (Marko et al., 2006).
Nonsynaptic GlyT1 may also have important role in the
regulation of nonsynaptic chemical neurotransmission, a novel
form in neuronal communication first described by Vizi (1984,
2005). Inhibitors of GlyT1 may participate in CNS drug actions
including their antipsychotic effects (Harsing et al., 2003).
Whether synaptic and nonsynaptic GlyT1s represent the same
or different splice variants of the transporter protein remains to
be elucidated (Thomsen, 2006).
In conclusion, the potential antipsychotic effects of GlyT1
inhibitors in human have been arisen since the early discovery
of this group of compounds (Toth and Lajtha, 1986; Javitt and
Frusciante, 1997). There are currently two GlyT1 inhibitors
(SSR504734 and JNJ-17305600) in human clinical phase I
investigation as antischizophrenic agents (Depoortere et al.,
2005; Thomsen, 2006). Our findings, that the GlyT1 inhibitors
Org-24461 and NFPS enhance firing rate of raphe serotonergic
neurons in vivo, may provide additional information about the
mode of antipsychotic action of GlyT1 inhibitor compounds.
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